Antibodies that bind urokinase plasminogen activator

Patent metadata

Field	Value
Publication number	US-9908944-B2
Application number	US-201414905409-A
Country	US
Kind code	B2
Filing date	Jul 15, 2014
Priority date	Jul 15, 2013
Publication date	Mar 6, 2018
Grant date	Mar 6, 2018

Abstract

The present invention relates to a method of identifying urokinase plasminogen activator (uPA) antibodies. The invention also relates to antibodies that are capable of binding uPA and which are capable of reducing or inhibiting uPA activity. Furthermore, the invention relates to uses for such antibodies, such as therapeutic and pharmaceutical uses.

First claim

The invention claimed is:

1. An antibody or antigen-binding fragment thereof that is capable of binding to human uPA, wherein the heavy chain of said antibody comprises:
a CDR1 sequence of amino acid residues 31 (Kabat and sequential) to 35 (Kabat and sequential) (SYTMS) of SEQ ID NO: 7; and
a CDR2 sequence of amino acids 50 (Kabat and sequential) to 65 (Kabat; 66 sequential) (TISGGGSHIYYADSVKG) of SEQ ID NO: 7; and
a CDR3 sequence of amino acid residues 95 (Kabat; 99 sequential) to 102 (Kabat; 108 sequential) (DGRDGSWFAY) of SEQ ID NO: 7 and wherein the light chain of said antibody comprises:
a CDR1 sequence of amino acid residues 24 (Kabat and sequential) to 34 (Kabat and sequential) (RTSQSIGDYLH) of SEQ ID NO: 8; and
a CDR2 sequence of amino acid residues 50 (Kabat and sequential) to 56 (Kabat and sequential) (YVSQSIS) of SEQ ID NO: 8; and
a CDR3 sequence of amino acid residues 89 (Kabat and sequential) to 97 (Kabat and sequential) (QNSHSFPLT) of SEQ ID NO: 8.

2. An antibody or antigen-binding fragment thereof that is capable of binding to human uPA, wherein the antibody is humanized and wherein the heavy chain comprises:
a CDR-H1 comprising SEQ ID NO: 9, located in amino acid residues 31-35 (Kabat); and
a CDR-H2 comprising SEQ ID NO: 10, located in amino acid residues 50-65 (Kabat); and
a CDR-H3 comprising SEQ ID NO: 11, located in amino acid residues 95-102 (Kabat)
and wherein the light chain comprises:
a CDR-L1 comprising SEQ ID NO: 12, located in amino acid residues 24-34 (Kabat); and
a CDR-L2 comprising SEQ ID NO: 13, located in amino acid residues 50-56 (Kabat); and
a CDR-L3 comprising SEQ ID NO: 14, located in amino acid residues 89-97 (Kabat).

3. An antibody or antigen-binding fragment thereof that is capable of binding to human uPA wherein said antibody comprises a heavy chain comprising SEQ ID NO: 21 and a light chain comprising SEQ ID NO:22.

Assignees

• Novo Nordisk As

Inventors

• Padkjaer Soeren
• Pass Jesper
• Roeder Gustav
• Almholt Kasper
• Usher Pernille A

Classifications

• A61P37/00

  Drugs for immunological or allergic disorders · CPC title

• A61P37/02

  Immunomodulators · CPC title

• A61P43/00

  Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00 · CPC title

• A61P29/00

  Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID] · CPC title

• G01N2500/04

  Screening involving studying the effect of compounds C directly on molecule A (e.g. C are potential ligands for a receptor A, or potential substrates for an enzyme A) · CPC title